Stock 003020 HEFEI LIFEON PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Hefei Lifeon Pharmaceutical Co., Ltd.

Equities

003020

CNE100004BD9

End-of-day quote Shenzhen S.E.
Other stock markets
 23:00:00 23/05/2024 BST 		5-day change 1st Jan Change
25.18 CNY +1.70% Intraday chart for Hefei Lifeon Pharmaceutical Co., Ltd. +7.33% -10.55%
05-21 Lifeon Pharmaceutical's Unit Gets Marketing Authorization for Loxoprofen Sodium Oral Solution MT
04-29 Hefei Lifeon Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • The group's high margin levels account for strong profits.
  • Analysts covering this company mostly recommend stock overweighting or purchase.

Weaknesses

  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the past year, analysts have significantly revised downwards their profit estimates.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
HEFEI LIFEON PHARMACEUTICAL CO., LTD. Stock Hefei Lifeon Pharmaceutical Co., Ltd.
-10.55% 555M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+38.51% 727B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+33.05% 599B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.23% 354B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.78% 328B
B-
ABBVIE INC. Stock AbbVie Inc.
+1.35% 277B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.00% 243B
B+
NOVARTIS AG Stock Novartis AG
+8.09% 205B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-5.77% 203B
A+
AMGEN INC. Stock Amgen Inc.
+6.19% 164B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 003020 Stock
  4. Ratings Hefei Lifeon Pharmaceutical Co., Ltd.